S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00450281 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 981

Last updated 2015-10-26

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about risk factors for lung cancer and may help the study of cancer in the future.

PURPOSE: This clinical trial is studying carcinogens in lung tissue from smokers (closed to entry as of 7/15/07) and non-smokers with newly diagnosed stage I, stage II, or stage III non-small cell lung cancer.

Conditions

Interventions

GENETIC

chromogenic in situ hybridization

GENETIC

gene expression analysis

GENETIC

mutation analysis

GENETIC

polymerase chain reaction

GENETIC

polymorphism analysis

OTHER

fluorescent antibody technique

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

OTHER

matrix-assisted laser desorption/ionization time of flight mass spectrometry

OTHER

study of socioeconomic and demographic variables

PROCEDURE

study of high risk factors

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH
  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Christine B. Ambrosone, PhD · Roswell Park Cancer Institute

  • Regina M. Santella, PhD · Herbert Irving Comprehensive Cancer Center

  • Kathy S. Albain, MD · Loyola University

  • Paul H. Gumerlock, PhD · University of California, Davis

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00450281 on ClinicalTrials.gov